Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection. 2010

R Turco, and M Martinelli, and E Miele, and E Roscetto, and M Del Pezzo, and L Greco, and A Staiano
Department of Pediatrics, University of Naples Federico II, Naples, Italy.

BACKGROUND Proton pump inhibitors (PPIs) and H(2) receptor antagonists (H(2)RAs) may play an important role on the onset of Clostridium difficile-associated disease (CDAD) in adults. The impact of Clostridium difficile on children treated with gastric acid-suppressing agents remains unknown. OBJECTIVE To investigate the relationship between CDAD and exposure to acid suppressive therapy in hospitalized paediatric patients. METHODS We reviewed the medical records of children, with a diagnosis of protracted diarrhoea and abdominal pain, whose stool was analysed for C. difficile toxins. We identified 68 patients with CDAD. For each patient, we randomly selected one control subjects with stool analysis negative for C. difficile. Comorbid illnesses, previous hospitalizations, antibiotics, corticosteroids, immunosuppressants and gastric acid suppressing exposures were recorded. RESULTS The use of PPI was significantly higher in C. difficile positive group compared with C. difficile negative group [odds ratio (OR): = 4.5; 95% confidence interval (CI) = 1.4-14.4]. We also found a trend for the use of H(2)RAs in patients infected by C. difficile compared with C. difficile negative comparison group (OR: = 3.8; 95% CI = 0.7-18.9). CONCLUSIONS Children exposed to PPIs therapy seem to be at higher risk for the development of Clostridium difficile-associated disease.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003967 Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight. Diarrheas
D004761 Enterocolitis, Pseudomembranous An acute inflammation of the INTESTINAL MUCOSA that is characterized by the presence of pseudomembranes or plaques in the SMALL INTESTINE (pseudomembranous enteritis) and the LARGE INTESTINE (pseudomembranous colitis). It is commonly associated with antibiotic therapy and CLOSTRIDIUM DIFFICILE colonization. Antibiotic-Associated Colitis,Clostridium Enterocolitis,Colitis, Pseudomembranous,Enteritis, Pseudomembranous,Pseudomembranous Colitis,Pseudomembranous Enteritis,Pseudomembranous Enterocolitis,Antibiotic Associated Colitis,Colitis, Antibiotic-Associated
D004812 Epidemiologic Methods Research techniques that focus on study designs and data gathering methods in human and animal populations. Epidemiologic Method,Epidemiological Methods,Methods, Epidemiologic,Epidemiological Method,Method, Epidemiologic,Method, Epidemiological,Methods, Epidemiological
D005260 Female Females
D006635 Histamine H2 Antagonists Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. Antihistaminics, H2,H2 Receptor Blockader,Histamine H2 Antagonist,Histamine H2 Blocker,Histamine H2 Receptor Antagonist,Histamine H2 Receptor Antagonists,Histamine H2 Receptor Blockader,Histamine H2 Receptor Blockaders,Antagonists, Histamine H2,Blockaders, Histamine H2 Receptor,H2 Receptor Blockaders,Histamine H2 Blockers,Receptor Antagonists, Histamine H2,Receptor Blockaders, H2,Antagonist, Histamine H2,Blockader, H2 Receptor,Blockaders, H2 Receptor,Blocker, Histamine H2,Blockers, Histamine H2,H2 Antagonist, Histamine,H2 Antagonists, Histamine,H2 Antihistaminics,H2 Blocker, Histamine,H2 Blockers, Histamine,Receptor Blockader, H2
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R Turco, and M Martinelli, and E Miele, and E Roscetto, and M Del Pezzo, and L Greco, and A Staiano
July 2003, The Journal of hospital infection,
R Turco, and M Martinelli, and E Miele, and E Roscetto, and M Del Pezzo, and L Greco, and A Staiano
July 2009, JAMA,
R Turco, and M Martinelli, and E Miele, and E Roscetto, and M Del Pezzo, and L Greco, and A Staiano
May 2010, Archives of internal medicine,
R Turco, and M Martinelli, and E Miele, and E Roscetto, and M Del Pezzo, and L Greco, and A Staiano
July 2010, World journal of gastroenterology,
R Turco, and M Martinelli, and E Miele, and E Roscetto, and M Del Pezzo, and L Greco, and A Staiano
May 2017, The American journal of gastroenterology,
R Turco, and M Martinelli, and E Miele, and E Roscetto, and M Del Pezzo, and L Greco, and A Staiano
October 2012, Current opinion in pediatrics,
R Turco, and M Martinelli, and E Miele, and E Roscetto, and M Del Pezzo, and L Greco, and A Staiano
October 2013, Mayo Clinic proceedings,
R Turco, and M Martinelli, and E Miele, and E Roscetto, and M Del Pezzo, and L Greco, and A Staiano
November 2013, The American journal of gastroenterology,
R Turco, and M Martinelli, and E Miele, and E Roscetto, and M Del Pezzo, and L Greco, and A Staiano
April 2014, The American journal of gastroenterology,
R Turco, and M Martinelli, and E Miele, and E Roscetto, and M Del Pezzo, and L Greco, and A Staiano
January 2014, Biomedical journal,
Copied contents to your clipboard!